ClinicalTrials.gg
Active, not recruitingNCT07090577MOPCASUpdated Sep 10, 2026

Multiomics Profiling of CSF in Cardiac Arrest Survivors

An observational study in Cardiac Arrest (CA), Hypoxic-Ischemic Brain Injury and Post-Resuscitation Syndrome, sponsored by Chungnam National University Hospital. Active, not recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Chungnam National University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Heart Arrest with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Heart Arrest · Korea, Republic of.

Enrollment
22nd of 22
15 · median 195
Started
2025
with 2 others
Observational
22 of 44
5 open now
Registered
41st of 44
by date
Lead sponsor
3 of 44
Chungnam National University Hospital

Among the 44 studies in Heart Arrest with a site in Korea, Republic of, this one is the 22nd largest by enrollment of the 22 observational ones that give a count, is one of 3 that started in 2025, is one of 22 observational ones, and was the 41st registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

8 of the 44 studies in Heart Arrest with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Heart Arrest with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this observational study is to identify further pathophysiologic mechanism of secondary brain injury following cardiac arrest by using serial multiomics profiling of serum and cerebrospinal fluid (CSF) samples. The main question it aims to answer is:

A. The main question it aims to answer is: What are the dynamic molecular changes in serum and CSF that reflect the pathophysiological mechanisms of secondary brain injury after cardiac arrest? B. What are the differences in serum and CSF multiomic signatures between varying severities of cardiac arrest, and how are these differences associated with the underlying pathophysiological mechanisms of secondary brain injury?

Serum and CSF samples that have already been prospectively collected from participants and stored in the BioBank will be used for this analysis.

03

Conditions studied

  • Cardiac Arrest (CA)
  • Hypoxic-Ischemic Brain Injury
  • Post-Resuscitation Syndrome

Keywords

  • cardiac arrest
  • hypoxic-ischemic brain injury
  • post-resuscitation syndrome
  • multiomics
  • cerebrospinal fluid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with an out-of-hospital cardiac arrest who underwent post-resuscitation care

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Out-of-hospital cardiac arrest (OHCA)
  • Patients who have received post-resuscitation care including temperature control due to unconsciousness (Glasgow Coma Score \< 8) after sustained ROSC.
  • Patients who consented to the placement of lumbar catheter for storing cerebrospinal fluid and blood samples in a human biobank.

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with a central nervous system-related disease before cardiac arrest
  • Patients who have undergone extracorporeal circulatory membrane oxygenation therapy
  • Patients who died within 24 hours from post-resuscitation care
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
15 participants (actual)
Patient registry
No

Groups and cohorts

  • good neurologic outcome

    Cerebral Performance Category (CPC) : 1 or 2

  • poor neurologic outcome

    Cerebral Performance Category (CPC) : 3 to 5

06

What researchers measure

Primary outcomes

  1. Neurological outcome

    Neurological outcome is evaluated using the Cerebral Performance Category (CPC) scale. The CPC score ranges from 1 to 5, where 1 indicates good cerebral performance (normal/mild disability), 2 indicates moderate cerebral disability, 3 indicates severe cerebral disability, 4 indicates coma or vegetative state, and 5 indicates brain death. Higher scores represent a worse neurological outcome.

    Time frame: after 6 months from return of spontaneous circulation

Secondary outcomes

  1. Illness severity score of cardiac arrest (rCAST)

    llness severity is assessed using the revised Post-Cardiac Arrest Syndrome for Therapeutic hypothermia (rCAST) score, which incorporates initial rhythm, blood pH, lactate levels, motor response, and arrest duration. The total score ranges from 0 to 15, with higher scores indicating greater illness severity and worse prognosis. Based on the total score, patients are categorized into three severity risk groups: low severity (0-5 points), moderate severity (6-8 points), and high severity (9-15 points), where the high-severity group reflects the worst clinical prognosis and highest risk of poor outcome.

    Time frame: immediately after return of spontaneous circulation

07

Study locations

1 site
08

References and documents

Publications

  • You Y, Park JS, Min JH, Jeong W, Ahn HJ, In YN, Jeon SY, Lee JK, Kang C. Blood-brain barrier permeability for the first 24 hours in hypoxic-ischemic brain injury following cardiac arrest. Resuscitation. 2024 May;198:110150. doi: 10.1016/j.resuscitation.2024.110150. Epub 2024 Feb 23. PubMed 38401708 ↗
  • Stopa V, Lileikyte G, Bakochi A, Agarwal P, Beske R, Stammet P, Hassager C, Arman F, Nielsen N, Devaux Y. Multiomic biomarkers after cardiac arrest. Intensive Care Med Exp. 2024 Sep 27;12(1):83. doi: 10.1186/s40635-024-00675-y. PubMed 39331333 ↗
  • Lileikyte G, Bakochi A, Ali A, Moseby-Knappe M, Cronberg T, Friberg H, Lilja G, Levin H, Arman F, Kjellstrom S, Dankiewicz J, Hassager C, Malmstrom J, Nielsen N. Serum proteome profiles in patients treated with targeted temperature management after out-of-hospital cardiac arrest. Intensive Care Med Exp. 2023 Jul 17;11(1):43. doi: 10.1186/s40635-023-00528-0. PubMed 37455296 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared publicly due to ethical and privacy concerns. However, data sharing may be possible upon reasonable request with prior approval from the ethics committee and the principal investigator

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Jul 29, 2025
StartActual
Jul 22, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07090577
Lead sponsor
Chungnam National University Hospital
Responsible party
Changshin Kang (Assistant professor, Chungnam National University Hospital) — Principal investigator
First posted
Jul 29, 2025
Start date
Jul 22, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Sep 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion